![Meghan Thomas](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Meghan Thomas is currently Vice President-Clinical Development at Argenica Therapeutics Ltd. since 2022.
Formerly, Dr. Thomas was Vice President-Clinical Programs & Operations at Zelira Therapeutics Ltd. Education includes undergraduate and doctorate degrees from The University of Western Australia and an undergraduate degree from the University of Edith Cowan.
| Unternehmen | Position | Beginn |
|---|---|---|
| ARGENICA THERAPEUTICS LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 04.04.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| ZELIRA THERAPEUTICS LIMITED | Geschäftsführer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
The University of Western Australia
 The University of Western Australia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Edith Cowan
 University of Edith Cowan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zelira Therapeutics Ltd.
 Zelira Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Manufactures and supplies cannabinoid-based medicines for the treatment of human diseases and disorders | Health Technology |
Argenica Therapeutics Ltd.
 Argenica Therapeutics Ltd. BiotechnologyHealth Technology Develops novel neuro protective therapeutics to reduce brain damage | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
Wählen Sie MarketScreener 
